XML 23 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities    
Net loss $ (52,666) $ (56,171)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization expense 2,499 1,936
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan 5,762 13,859
Stock-based compensation - PAVmed Inc. 2014 Equity Plan 1,060 1,132
Change in fair value - Senior Secured Convertible Note 2,980
Loss on issue - Senior Secured Convertible Note 1,111
Debt extinguishment loss - Senior Secured Convertible Note 26
APA-RDx: Issue common stock - termination payment 713 653
Issue common stock - vendor service agreement 23
Changes in operating assets and liabilities:    
Accounts receivable (28) 183
Prepaid expenses and other current assets (1,160) 1,163
Accounts payable 89 (445)
Accrued expenses and other current liabilities 2,394 333
Due To: PAVmed Inc. - operating expenses, employee related costs, MSA Fee 4,380 7,672
Net cash flows used in operating activities (32,817) (29,685)
Cash flows from investing activities    
Purchase of equipment (221) (908)
Asset acquisition (3,200)
Net cash flows used in investing activities (221) (4,108)
Cash flows from financing activities    
Proceeds – issue of preferred stock 18,625
Proceeds – issue of Senior Convertible Note 10,000
Proceeds – issue of common stock – Committed Equity Facility 1,807
Proceeds – issue of common stock – At-The-Market Facility 284
Proceeds – exercise of stock options 695
Proceeds – issue common stock – Employee Stock Purchase Plan 551 109
Net cash flows provided by financing activities 29,460 2,611
Net increase (decrease) in cash (3,578) (31,182)
Cash, beginning of period 22,474 53,656
Cash, end of period $ 18,896 $ 22,474